Alerts will be sent to your verified email
Verify EmailBLISSGVS
|
Bliss GVS Pharma
|
Gufic Biosciences
|
Novartis
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
2.7 % | 1.28 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
6.83 % | 16.89 % | 8.11 % |
|
5yr average Equity Multiplier
|
1.3 | 2.16 | 2.72 |
|
5yr Average Asset Turnover Ratio
|
0.62 | 0.75 | 0.18 |
|
5yr Avg Net Profit Margin
|
8.7 % | 10.24 % | 17.12 % |
|
Price to Book
|
2.55 | 4.73 | 3.8 |
|
P/E
|
26.46 | 59.7 | 33.36 |
|
5yr Avg Cash Conversion Cycle
|
186.56 Days | -15.25 Days | -23.33 Days |
|
Inventory Days
|
54.35 Days | 71.73 Days | 44.27 Days |
|
Days Receivable
|
189.93 Days | 106.89 Days | 38.18 Days |
|
Days Payable
|
75.78 Days | 179.29 Days | 124.28 Days |
|
5yr Average Interest Coverage Ratio
|
14.68 | 8.9 | 65.43 |
|
5yr Avg ROCE
|
13.27 % | 17.89 % | 5.91 % |
|
5yr Avg Operating Profit Margin
|
17.03 % | 18.12 % | 15.15 % |
|
5 yr average Debt to Equity
|
0.11 | 0.67 | 0.0 |
|
5yr CAGR Net Profit
|
4.24 % | -2.66 % | 37.01 % |
|
5yr Average Return on Assets
|
5.31 % | 7.7 % | 3.13 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
35.36 % | 72.5 % | 70.68 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.32 % | -2.5 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 2.6 % | 0.0 |
|
Bliss GVS Pharma
|
Gufic Biosciences
|
Novartis
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|